Fintel reports that on January 2, 2025, Piper Sandler downgraded their outlook for Biogen (SNSE:BIIB) from Overweight to Neutral. There are 1,768 funds or institutions reporting positions in Biogen.

Fintel reports that on January 2, 2025, Piper Sandler downgraded their outlook for Biogen (BRSE:BIIB) from Overweight to Neutral. There are 1,768 funds or institutions reporting positions in Biogen.

Fintel reports that on January 2, 2025, Piper Sandler downgraded their outlook for Biogen (WBAG:BIIB) from Overweight to Neutral. There are 1,768 funds or institutions reporting positions in Biogen.

Analysts' ratings for Biogen (NASDAQ:BIIB) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The following table summarizes their recent ratings, shedding light on ...

BIIB is a #3 (Hold) on the Zacks Rank, with a VGM Score of B. It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 9.31; value investors ...

Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new ...

Piper Sandler downgraded Biogen (BIIB) to Neutral from Overweight with a price target of $138, down from $315, following a transfer of coverage. Biogen remains in transition, as management ...

Biogen (BIIB) stock slipped as Piper Sandler downgraded the company to neutral from overweight, citing challenges in Alzheimer's drug market. Read more here.

Biogen Inc. (NASDAQ:BIIB – Get Free Report) was the target of a significant decrease in short interest in the month of ...

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by research analysts at Piper Sandler from an “overweight” rating to a “neutral” rating in a research report issued on Thursday ...

BIIB closed Tuesday's trading at $152.92 ... views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

Piper Sandler downgraded Biogen (NASDAQ:BIIB) to neutral from overweight on Thursday, citing, among other things, the company's challenges in establishing its presence in the market for Alzheimer ...